9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results – 37% Biosimilar Growth
On 9 August 2024, Sandoz announced its Q2 2024 sales and financial results for half year ended 30 June 2024, reporting net sales of USD 2.6 billion for Q2/24, an increase of 9% when compared to the same quarter in 2023… Read more here.
9 August 2024 | Celltrion’s ZymfentraTM (SC Infliximab) Listed on 26 US Formularies Five Months Post Launch
On 9 August 2024, Celltrion announced that its Zymfentra™ (infliximab-dyyb) has been included in 26 US formularies, including for 3 major Prescription Benefit Managers (PBMs), just five months after launch… Read more here.
9 August 2024 | NZ | NZ’s Pharmac Announces Future Procurement Opportunity for Bevacizumab
On 9 August 2024, New Zealand’s Pharmaceutical Medicines Agency (Pharmac) announced that it is seeking commercial bids from suppliers for the supply of bevacizumab for a range of cancers… Read more here.
9 August 2024 | MSD to Acquire Bispecific Antibody Targeting B-Cell Associated Diseases from Curon Biopharmaceutical
On 9 August 2024, MSD and Curon Biopharmaceutical announced the MSD acquisition of Curon developed CD3xCD19 bispecific antibody CN201, currently in Ph I/II trials for the treatment of B-cell associated diseases… Read more here.
8 August 2024 | Biocon Reports 30% YOY Revenue Growth for Q2/24, Biosimilars Up 11%
On 8 August 2024, Biocon Limited reported year on year consolidated revenue growth of 30% for Q2 2024, primarily as a result of a “one-time gain” from the strategic collaboration between Biocon and Eris Lifesciences… Read more here.
7 August 2024 | AU | Fresenius Withdraws Adalimumab Biosim from AU Market
Fresenius Kabi has walked away from the Australian adalimumab market and cancelled its approvals for 40mg Idacio® pre-filled syringe and 40mg Idacio® pen products which were approved as biosimilars to AbbVie’s Humira®… Read more here.
7 August 2024 | Novo Nordisk Profits Soar in 2024 Mid-Year Report
On 7 August 2024, Novo Nordisk released its financial report which showed a strong increase in profits in the first half of 2024. Novo Nordisk’s total sales equalled DKK 133.4 billion in the first six months of 2024… Read more here.
6 August 2024 | KR | Celltrion Denosumab Phase 3 Study Results
As reported in April this year, Celltrion presented the 78-week results of its Phase 3 study of CT-P41, biosimilar to Amgen’s Prolia® (denosumab), at the World Congress on Osteoporosis held in London from 11-14 April 2024,… Read more here.
6 August 2024 | NZ | MSD’s Keytruda® Receives Early Access Funding After Reversal of Health NZ Decision
On 6 August 2024, Health New Zealand announced that it will now allow a small group of cancer patients to receive free early access to MSD’s Keytruda® (pembrolizumab) despite deciding earlier this week that it would not do so… Read more here.
6 August 2024 | Amgen Reports Q2/24 Results – Total Revenue Increase of 20% to US$8.4B
On 6 August 2024, Amgen announced its financial results for Q2/2024, reporting total revenues increased 20% to US$8.4 billion compared with Q2/2023. Twelve of its products delivered at least double-digit sales growth in the quarter,… Read more here.
5 August 2024 | US | EMA | Lupin Completes Phase III Biosimilar Ranibizumab Trials
On 5 August 2024, Lupin announced the successful completion of a global Phase III clinical study of LUBT010, its biosimilar to Genentech’s Lucentis® (ranibizumab)… Read more here.
About Pearce IP
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys to the life sciences industries (in particular, pharmaceutical, biopharmaceutical, biotech, ag-tech and food tech). Pearce IP is the 2021 ‘Intellectual Property Team of the Year’ (Lawyers Weekly Australian Law Awards) and was shortlisted for the same award in 2022. Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a ‘5 Star’ firm, and the Legal 500 APAC Guide for Intellectual Property.
Our leaders have been recognised in virtually every notable IP listing for their legal, patent and trade mark excellence including: IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WIPR Leaders, 5 Star IP Lawyers, Best Lawyers, and Australasian Lawyer 5 Star Awards, and have been honoured with many awards including Australian Law Awards – IP Partner of the Year, Women in Law Awards – Partner of the Year, Women in Business Law Awards - Patent Lawyer of the Year (Asia Pacific), Most Influential Lawyers (Changemaker), among other awards.
Naomi Pearce
CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)
Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry. Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.
Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”. Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.
Chantal Savage
Special Counsel, Lawyer
Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom and now at Pearce IP.
With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.
Rosie Stramandinoli
Executive (Acting) Patent & Trade Mark Attorney
Rosie is a highly accomplished and experienced patent attorney and strategist with a passion for innovation and growth. She manages complex local and global matters for clients in the life sciences industries, including the pharmaceutical, biopharmaceutical, biotech, med-tech, animal health, food and cosmetic industries.
Rosie has more than X years’ experience as a patent attorney, and has a background in chemistry. She has won multiple accolades for her work as an IP practitioner, including a Silver Globee Award for Committed Professional of the Year (2023) and recognition as one of the top 250 leading female IP practitioners (2019). Managing Intellectual Property, IAM Patent 1000, and Asia IP Experts, amongst others, have also commended Rosie as one of Australia’s leading patent practitioners.
Imogen Bain
Paralegal
Imogen is a paralegal supporting Pearce IP’s legal and trade mark teams. Imogen prepares patent litigation updates, conducts legal research, and provides paralegal and administrative assistance.
Imogen comes from a background working in hospitality, where she has learnt how to be an effective communicator and work efficiently. Imogen has an interest in the design space, having completed her Certificate III in Design Fundamentals. Her knowledge of the design industry has improved her understanding of the IP realm and has strengthened her passion for IP law. Imogen is a highly disciplined and organised individual who works to assist her colleagues with dedication and optimism.